GSK launches 'More than Medicine' corporate blog

Share this article:
GlaxoSmithKline announced the launch of a corporate blog for the US, titled More than Medicine. The blog went live last January.

Topics covered so far range from healthcare policy news and GSK financial reports, to relieving stress and avoiding sunburn. According to a statement on the blog, its goal is to “encourage an open, productive discussion about a range of topics related to the US healthcare system and how it can be improved.”

Michael Fleming, senior director of social media at GSK, told PRWeek that GSK “would like people to hear from our company and interact with our company in…a less formal, less rigid way than they are used to hearing from us,” noting that the kind of dialogue featured on the blog is “not being offered by any other company.”

Several healthcare bloggers have already questioned More than Medicine's authorship – articles contain a first name but not a last name – leading to a post on Thursday titled “Content is King Here, Not the One Who Posts It." The author, Michael F – most likely Michael Fleming – wrote in the post that “legitimate privacy and security concerns” limit the amount of personal information the authors can provide externally. “One of us has already been quoted in the press about this blog, so we're certainly not hiding anything; but the larger point is that this blog is not about any of us individually; it is about the company as a whole,” wrote Michael F.

Marc Monseau, the editor of Johnson & Johnson's corporate blog JNJ BTW, commended GSK on the launch in a comment on More than Medicine, and reiterated the need for a “candid, constructive dialogue” about how pharmaceutical companies “can be part of the conversation about health and healthcare issues on the social web.”
Share this article:

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Rep access continues to shrink

Rep access continues to shrink

Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.